The history and future of population pharmacokinetic analysis in drug development

References

• Amidon GL, Paul MJ, Welling PG. Model-independent prediction methods in pharmacokinetics: Theoretical considerations. Math Biosci. 1975 25(3-4):259-72.
   Google Scholar
• Ayral G, Si Abdalla J-F, Magnard C, Chauvin J. A novel methods based on unbiased correlations tests for covariate selection in nonlinear mixed effects models: The COSSAC approach. CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):318-329. doi: 10.1002/psp4.12612.
   Google Scholar
• Bass L. Current models of hepatic elimination. Gastroenterology. 1979 Jun;76(6):1504-5.
   Google Scholar
• Beckett AH, Rowland M. Urinary excretion kinetics of amphetamine in man. J Pharm Pharmac. 1965 Oct;17(10):628-39. doi: 10.1111/j.2042-7158.1965.tb07575.x.
   Google Scholar
• Benet LZ. General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J Pharm Sci. 1972 Apr;61(4):536-41. doi: 10.1002/jps.2600610408.
   Google Scholar
• Bies RR, Muldoon MF, Pollock BG, Manuck S, Smith G, Sale ME. A genetic algorithm-based, hybrid machine learning approach to model selection. J Pharmacokinet Pharmacodyn. 2006 Apr;33(2):195-221. doi: 10.1007/s10928-006-9004-6.
   Google Scholar
• Boström E, Simonnsson US, Hammarlund-Udenaes M. In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos. 2006 Sep;34(9):1624-31. doi: 10.1124/dmd.106.009746.
   Google Scholar
• Box GEP. Robustness in the Strategy of Scientific Model Building. Launer RL, Wilkinson GN, editors. Cambridge (MA): Academic Press; 1979.
   Google Scholar
• Cucinell SA, Conney AH, Sansur M, Burns JJ. Drug interactions in man I. Lowering effect of phenobarbital on plasma levels of bishydroxycoumarine (Dicumarol) and diphenylhydantoin (Dilantin). Clin Pharmacol Ther. 1965 Jul-Aug;6:420-9. doi: 10.1002/cpt196564420.
   Google Scholar
• Dedrick RL, Bischoff KB. Pharmacokinetics in applications of the artificial kidney. Chem Engng Progr Symp Ser. 1968 64(84):32-44.
   Google Scholar
• Dost FH. Der Blutspiegel-Kinetic der Konzentrationsabläufe in der Krieslauffüssigkeit. Leipzig: G Thieme; 1953.
   Google Scholar
• Earp JC, Pyszczynski NA, Molano DS, Jusko WJ. Pharmacokinetics of dexamethasone in a rat model of rheumatoid arthritis. Biopharm Drug Dispos. 2008 Sep;29(6):366–72. doi: 10.1002/bdd.626.
   Google Scholar
• [EMA] European Medicines Agency. Guideline on reporting the results of population pharmacokinetic analyses. London: European Medicines Agency; 2007.
   Google Scholar
• [FDA] Food and Drug Administration. Guidance for Industry: Population Pharmacokinetics. Washington, DC: United States Food and Drug Administration; 1999.
   Google Scholar
• [FDA] Food and Drug Administration. Guidance for Industry: Population Pharmacokinetics. Washington, DC: United States Food and Drug Administration; 2022.
   Google Scholar
• Himmelstein KJ, Lutz RJ. A review of the applications of physiologically based pharmacokinetic modeling. J Pharmacokinet Biopharm. 1979 Apr;7(2):127-45. doi: 10.1007/BF01059734.
   Google Scholar
• Ismail M, Sale M, Yu Y, Pillai N, Liu S, Pflug B, Bies R. Development of a genetic algorithm and NONMEM workbench for automating and improving population pharmacokinetic/pharmacodynamic model selection. J Pharmacokinet Pharmacodyn. 2022 Apr;49(2):243-256. doi: 10.1007/s10928-021-09782-9.
   Google Scholar
• Jusko WJ. A pharmacodynamic model for cell cycle-specific chemotherapeutic agents. J Pharmacokinet Biopharm. 1973 Jun;1(3):175-200.
   Google Scholar
• Khatri A, Gaber MW, Brundage RC, Naimark MD, Hanna SK, Stewart CF, Kirstein MN. Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid. Cancer Chemother Pharmacol. 2011 Sep;68(3):721-31. doi: 10.1007/s00280-010-1542-3.
   Google Scholar
• Kursa MB, Jankowski A, Rudnicki WR. Boruta – a system for feature selection. Fundamenta Informaticae. 2010 101(4):271-85. doi: 10.3233/FI-2010-288.
   Google Scholar
• Kursa MB, Rucnicki WR. Feature selection with the boruta package. J Stat Softw. 2010 Sep 36(11):1-13. doi: 10.18637/jss.v036.i11.
   Google Scholar
• Levy G, Yacobi A. Effect of plasma protein binding on elimination of warfarin. J Pharm Sci. 1974 May;63(5):805-6. doi: 10.1002/jps.2600630539.
   Google Scholar
• Liu C, Xu Y, Liu Q, Zhu H, Wang Y. Application of machine learning based methods in exposure-response analysis. J Pharmacokinet Pharmacodyn 2022 Aug;49(4):401-410. doi: 10.1007/s10928-022-09802-2.
   Google Scholar
• Liu X, Liu C. Huang R, Zhu H, Liu Q, Mitra S, Wang Y. Long short-term memory recurrent neural network for pharmacokinetic-pharmacodynamic modeling. Int J Clin Pharmacol Ther. 2021 Feb;59(2):138-146. doi: 10.5414/CP203800.
   Google Scholar
• Liu X, Want Y. Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn 2016 Aug;43(4):359-370. doi: 10.1007/s10928-016-9476-y.
   Google Scholar
• Lledó-García R, Nácher A, Casabó VG, Merino-Sanjuán M. A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat. Drug Metab Dispos. 2011 Feb;39(2):294-301. doi: 10.1124/dmd.110.034488.
   Google Scholar
• Lu J, Bender B, Jin J, Guan Y. Deep learning prediction of patient response time course from early data via neural-pharmacokinetic/pharmacodynamic modeling. Nat Mach Intell. 2021 Jun;3:696-704. doi: 10.1038/s42256-021-00357-4.
   Google Scholar
• Ludden TM. Population pharmacokinetics. J Clin Pharmacol. 1988 Dec;28(12):1059-63. doi: 10.1002/j.1552-4604.1988.tb05714.x.
   Google Scholar
• Madabushi R, Seo P, Zhao L, Tegenge M, Zhu H. Review: Role of model-informed drug development approaches in the lifecycle of drug development and regulatory decision-making. Pharm Res. 2022;39(8):1669-1680. doi: 10.1007/s11095-022-03288-w.
   Google Scholar
• Newburger J, Wagner JG, Stavchansky S. A method to predict infinity values for bioexponential processes. J Pharmacokinet Biopharm. 1979 Aug;7(4):417-25. doi: 10.1007/BF01062539.
   Google Scholar
• Moore G. Progress in Digital Integrated Electronics. 1975 IEEE Text Speech. Intel Corporation. 1975.
   Google Scholar
• Pang KS, Rowland M. Hepatic clearance of drugs I. Theoretical consideration of a ‘well stirred’ model and a ‘parallel tube’ model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Phamacokinet Biopharm. 1977 Dec;5(6):625-53. doi: 10.1007/BF01059688.
   Google Scholar
• Pang KS, Rowland M. Hepatic clearance of drugs II. Experimental evidence for acceptance of the ‘well-stirred’ model over the ‘parallel tube’ model using lidocaine in the perfused rate liver in situ preparation. J Phamacokinet Biopharm. 1977 Dec;5(6):655-80. doi: 10.1007/BF01059689.
   Google Scholar
• Pang KS, Rowland M. Hepatic clearance of drugs III. Additional experimental evidence supporting the ‘well-stirred’ model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ preparation. J Phamacokinet Biopharm. 1977 Dec;5(6):681-99. doi: 10.1007/BF01059690.
   Google Scholar
• Pfister M, Zhang L, Hammarlund-Udenaes M, Sheiner LB, Gerber CM, Täuber MG, Cottagnoud P. Modeling of transfer kinetics at the serum–cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin. Antimicrob Agents Chemother. 2003 Jan;47(1):138–43. doi: 10.1128/AAC.47.1.138-143.2003.
   Google Scholar
• Porzio S. Application of population pharmacokinetics for preclinical safety and efficacy studies. Bioanalysis. 2013 Aug;5(16):2053-69. doi: 10.4155/bio.13.147.
   Google Scholar
• Prague M, Lavielle M. SAMBA: A novel method for fast automatic model building in nonlinear mixed-effects models. CPT Pharmacometrics Syst. Pharmacol. 2022 Feb;11(2):161-172. doi: 10.1002/psp4.12742.
   Google Scholar
• Purdue P. Stochastic theory of compartments: One and two compartment systems. Bltn Mathcal Biology. 1974 Oct;36:577-88.
   Google Scholar
• Radivojevic A, Corrigan B, Downie N, Fox R, Fiedler-Kelly J, Liu H, Melhem M, Radke D, Schaefer P, Su J, et al. Data standards for model-informed drug development: an ISOP initiative. J Pharmacokinet Pharmacodyn. 2018 Oct;45(5):659-661. doi: 10.1007/s10928-018-9595-8.
   Google Scholar
• Rebai I, Duval V, Akil A, Teuscher N, Largajolli A, Fauchet F. Evaluation of the Boruta machine learning algorithm for covariate selection. Abstract 10415. Poster session presented at: 31st PAGE meeting. 2023 Jun 28-30; Palexco A Coruña, Spain.
   Google Scholar
• Sale M, Sherer EA. A genetic algorithm based global search strategy for population pharmacokinetic/pharmacodynamic model selection. Br J Clin Pharmacol. 2015 Jan;79(1):28-39. doi: 10.1111/bcp.12179.
   Google Scholar
• Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menden model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980 Dec;8(6):553-71. doi: 10.1007/BF01060053.
   Google Scholar
• Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. II. Bioexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1981 Oct;9(5):635-51. doi: 10.1007/BF01061030.
   Google Scholar
• Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1983 Jun;11(3):303-19. doi: 10.1007/BF01061870.
   Google Scholar
• Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977 Oct;5(5):445-79. doi: 10.1007/BF01061728.
   Google Scholar
• Sherer EA, Sale ME, Pollock BG, Belani CP, Egorin MJ, Ivy PS, Lieberman JA, Manuck SB, Marder SR, Muldoon MF, et al. Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. J Pharmacokinet Pharmacodyn. 2012 Aug;39(4):393-414. doi: 10.1007/s10928-012-9258-0.
   Google Scholar
• Silber HE, Burgener C, Letellier IM, Peyrou M, Jung M, King JN, Gruet P, Giraudel JM. Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis. Pharm Res. 2010 Dec;27(12):2633-45. doi: 10.1007/s11095-010-0262-z.
   Google Scholar
• Sjödin L, Visser S, Al-Saffar A. Using pharmacokinetic modeling to determine the effect of drug and food on gastrointestinal transit in dogs. J Pharmacol Toxicol Methods. 2011 Jul-Aug;64(1):42-52. doi: 10.1016/j.vascn.2011.04.008.
   Google Scholar
• Tait JF. The use of isotopic steroid for the measurement of production rates in vivo. J Clin Endocr Metab. 1963 Dec;23:1285-97. doi: 10.1210/jcem-23-12-1285.
   Google Scholar
• Tang A. Machine learning for pharmacokinetic/pharmacodynamic modeling. J Pharm Sci. 2023 May;112(5):1460-1475. doi: 10.1016/j.xphs.2023.01.010.
   Google Scholar
• Vanapalli SR, Hung YP, Fleckenstein L, Dzimianski MT, McCall JW. Pharmacokinetics and dose proportionality of oral moxidectin in Beagle dogs. Biopharm Drug Dispos. 2002 Oct;23(7):263–72. doi: 10.1002/bdd.313.
   Google Scholar
• Vaughan DP, Trainor A. Derivation of general equations for linear mammillary models when the drug is administered by different routes. J Pharmacokinet Biopharm. 1975 Jun;3(3):203-18. doi: 10.1007/BF01067909.
   Google Scholar
• Vozeh S, Steimer JL, Rowland M, Morselli P, Mentre F, Balant LP, Aarons L. The use of population pharmacokinetics in drug development. Clin Pharmacokinet 1996 Feb 30(2):81-93. doi: 10.2165/00003088-199630020-00001.
   Google Scholar
• Wagner JG. Biopharmaceutics and Relevant Pharmacokinetics. Hamilton (IL): Drug Intelligence Publications; 1971.
   Google Scholar
• Wagner JG. A modern view of pharmacokinetics. J Pharmacokinet Biopharm. 1973 Oct;1(5):363-401. doi: 10.1007/BF01059664.
   Google Scholar
• Wagner JG. History of pharmacokinetics. Pharmacol Ther. 1981;12(3):537-62. doi: 10.1016/0163-7258(81)90097-8.
   Google Scholar
• Wagner JG, Ayres JW. Bioavailability assessment: methods to estimate total area (AUC 0 to infinity) and total excreted (A infinity e) and importance of blood and urine sampling scheme with application to digoxin. J Pharmacokinet Biopharm. 1977 Oct;5(5):533-57. doi: 10.1007/BF01061733.
   Google Scholar
• Wagner JG, Northam JI, Always CD, Carpenter OS. Blood levels of drug at the equilibrium state after multiple dosing. Nature. 1965 Sep;207(5003):1301-2. doi: 10.1038/2071301a0.
   Google Scholar
• Yacobi A, Levy G. Comparative pharmacokinetics of coumarin anticoagulants XIV: Relationship between protein binding, distribution, and elimination kinetics of warfarin in rats. J Pharm Sci. 1975 Oct;64(10):1660-4. doi: 10.1002/jps.2600641015.
   Google Scholar
• Yacobi A, Levy G. Comparative pharmacokinetics of coumarin anticoagulants XXI: Effect of plasma protein binding on distribution kinetics of warfarin in rats. J Pharm Sci. 1977 Apr;66(4):567-72. doi: 10.1002/jps.2600660428.
   Google Scholar